

CLAIMS


1. A compound of general formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof:



wherein:

s is an integer equal to 1 or 2;


R is selected from the following Angiotensin II Receptor Blocker residues of formula (II) or (III):



(II)


wherein:

R₀ is




15 or -N₀ which is a group capable to bind to Y, having one of the following meaning:

-COO-, -O-, -CONH-, -OCO-, -OCOO- or




20 wherein R' and R'' are the same or different, and are H or straight or branched C₁-C₄ alkyl;


R₁ is selected from the group consisting of:




(IIa)



(IIb)




(IIc)




(IIId)

or



(IIe)

wherein m is an integer equal to 0 or 1 and N_0 is as above defined;



(III)


wherein N_1 has the same meaning as N_0 or is equal to $-COOH$; with the proviso that at least one of the groups N_1 is equal to $-COO-$ or $-CONH-$, i.e. it is a group capable to bind to Y;

5 Y is a bivalent radical having the following meaning:


a)

- straight or branched C_1-C_{20} alkylene, preferably C_1-C_{10} , being optionally substituted with one or more of the substituents selected from the group consisting of: halogen atoms, hydroxy, $-ONO_2$ or T_0 , wherein T_0 is $-OC(O)(C_1-C_{10} \text{ alkyl})-ONO_2$ or $-O(C_1-C_{10} \text{ alkyl})-ONO_2$;
- cycloalkylene with 5 to 7 carbon atoms into cycloalkylene ring, the ring being optionally substituted with side chains T, wherein T is straight or branched alkyl with from 1 to 10 carbon atoms, preferably CH_3 ;

b)




c)



20 wherein n is an integer from 0 to 20, and n^1 is an integer from 1 to 20;

d)




wherein:

25 n^1 is as defined above and n^2 is an integer from 0 to 2;

$X_1 = -OCO-$ or $-COO-$ and R^2 is H or CH_3 ;

e)




wherein:

n¹, n², R² and X₁ are as defined above;

Y¹ is -CH₂-CH₂- or -CH=CH-(CH₂)_{n²}-;

5 f)



wherein:

n¹ and R² are as defined above, R³ is H or -COCH₃;


with the proviso that when Y is selected from the bivalent
10 radicals mentioned under b)-f), the -ONO₂ group is linked
to a -(CH₂)_{n¹} group;

g)



wherein X₂ is -O- or -S-, n³ is an integer from 1 to 6,
15 preferably from 1 to 4, R² is as defined above;

h)




wherein:

n⁴ is an integer from 0 to 10;

20 n⁵ is an integer from 1 to 10;


R⁴, R⁵, R⁶, R⁷ are the same or different, and are H or
straight or branched C₁-C₄ alkyl, preferably R⁴, R⁵, R⁶, R⁷
are H;

wherein the -ONO₂ group is linked to




wherein n⁵ is as defined above;

Y² is an heterocyclic saturated, unsaturated or aromatic 5
5 or 6 members ring, containing one or more heteroatoms
selected from nitrogen, oxygen, sulfur,
and is selected from




15 **2.** A compound of general formula (I) or a pharmaceutically
acceptable salt or stereoisomer thereof according to claim
1 wherein Y is a bivalent radical having the following
meaning:

- a) straight or branched C₁-C₁₀ alkylene, being optionally
20 substituted with T₀, wherein T₀ is as above defined;
- b)




wherein n is an integer equal to 0 or 1, and n^1 is an integer equal to 1; with the proviso the $-\text{ONO}_2$ group is linked to a $-(\text{CH}_2)_{n^1}$ group;

5 g)




wherein X_2 is $-\text{O}-$ or $-\text{S}-$, n^3 is an integer equal to 1 and R^2 is H.

10 **3.** A compound according to claims 1-2, selected from the group consisting of:




(1)




(2)


15




(3)




(4)




(5)




(6)




(7)




(8)




(9)




(10)




(11)




(12)




(13)




(14)




(15)




(16)




(17)




(18)




(19)




(20)




(21)




(22)




(23)




(24)




(25)




(26)




(27)




(28)




(29)




(30)




(31)




(32)




(33)




(34)




(35)




(36)




(37)




(38)




(39)




(40)




(41)






(42)




(43)




(44)









(48)




(49)




(50)









(54)



(55)




(56)




CCCC1=CNC(C1)/C=C/C(Cc2ccsc2)C(=O)Oc3ccc(CON=O)cc3C(=O)Oc4ccc(CON=O)cc4CCCC1=N[C@H](Cc2ccc(cc2)C(=O)OCc3ccccc3COC(=O)O)C=C(C1)C(=O)OCc4ccccc4COC(=O)O


5



(62)




(63)




(64)

5




(65)




(66)

10




(67)




(68)


5




(69)




(70)




(71)




(72)




(73)




(74)




(75)




(76)




(77)



(78)



(79)



(80)

5

4. A compound of general formula (I) according to claims 1-3 for use as a medicament.

5. Use of a compound according to claims 1-3 for preparing
10 a drug having anti-inflammatory, antithrombotic and antiplatelet activity.

6. Use of a compound according to claims 1-3, for preparing
a drug that can be employed in the treatment or prophylaxis
15 of cardiovascular, renal and chronic liver diseases, inflammatory processes and metabolic syndromes.

7. Use of a compound according to claim 6, for preparing a drug that can be employed in the treatment or prophylaxis of heart failure, myocardial infarction, ischemic stroke, atherosclerosis, ocular and pulmonary hypertension, hypertension, diabetic nephropathy, peripheral vascular diseases, left ventricular dysfunction and hypertrophy, liver fibrosis and portal hypertension.
8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of general formula (I) or a salt or stereoisomer thereof according to claims 1-3.
9. A pharmaceutical composition according to claim 8 in a suitable form for the oral, parenteral, rectal, topic and transdermic administration, by inhalation spray or aerosol or iontophoresis devices.
10. Liquid or solid pharmaceutical composition for oral, parenteral, rectal, topic and transdermic administration or inhalation in the form of tablets, capsules and pills eventually with enteric coating, powders, granules, gels, emulsions, solutions, suspensions, syrups, elixir, injectable forms, suppositories, in transdermal patches or liposomes, containing a compound of formula (I) or a salt or stereoisomer thereof according to claims 1-3 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising a compound of general formula (I), at least a compound used to treat cardiovascular disease and a pharmaceutically acceptable carrier.

12. Pharmaceutical composition according to claim 11 wherein the compound used to treat cardiovascular disease is selected from the group consisting of: ACE inhibitors, HMGCoA reductase inhibitors, beta-adrenergic blockers, calcium channel blockers, diuretics, antithrombotics such as aspirin, nitrosated ACE inhibitors, nitrosated HMGCoA reductase inhibitors, nitrosated beta-adrenergic blockers, nitrosated aspirin and nitrosated diuretics.

10

13. A pharmaceutical kit comprising a compound of general formula (I) as defined in claim 1, a compound used to treat cardiovascular disease as combined preparation for simultaneous, separated, sequential use for the treatment of cardiovascular disease.

15

14. A pharmaceutical kit according to claim 13 wherein the compound used to treat cardiovascular disease is selected from the group consisting of: ACE inhibitors, HMGCoA reductase inhibitors, beta-adrenergic blockers, calcium channel blockers, diuretics, antithrombotics such as aspirin, nitrosated ACE inhibitors, nitrosated HMGCoA reductase inhibitors, nitrosated beta-adrenergic blockers, nitrosated aspirin and nitrosated diuretics.

20
25